In pharmaceutical fraud cases, the headline-making numbers are usually the millions paid in settlements. But sometimes the more interesting figure is the amount paid to the people who first raised the alarm. In one notable federal health care fraud matter, two former pharmaceutical employees are receiving more than $250,000 after information they provided helped expose an alleged kickback arrangement involving a specialty drug distributor and a free inventory management system.
On December 13, 2024, the U.S. Department of Justice announced that ASD Specialty Healthcare LLC, doing business as Besse Medical, agreed to pay $1.67 million to resolve allegations that it violated the federal Anti-Kickback Statute and the False Claims Act. The government alleged that the company provided specialized inventory management technology to retina practices at no charge in order to encourage those practices to purchase pharmaceutical products from the distributor.
The whistleblowers, Julianne Nunnelly and Matthew Shanks, are former employees of Regeneron Pharmaceuticals. Under the False Claims Act’s qui tam provisions, they are set to receive $250,705.20 from the settlement proceeds. It is an eye-catching reward, but the case is about much more than a six-figure check. It provides a useful look at how pharmaceutical incentives, software, Medicare reimbursement, federal anti-fraud laws, and whistleblower protections can collide in ways that are considerably more complicated than somebody sliding an envelope of cash across a restaurant table.
What Happened in the Besse Medical Pharmaceutical Fraud Case?
ASD Specialty Healthcare operates as Besse Medical and distributes specialty medical and pharmaceutical products to physician practices around the United States. Its products include injectable medicines used by ophthalmologists and retina specialists treating conditions such as neovascular, or “wet,” age-related macular degeneration.
Wet AMD can damage central vision when abnormal blood vessels develop and leak beneath the retina. Anti-VEGF injections are among the most common treatments used to slow or prevent additional vision loss, according to the National Eye Institute. These treatments may require repeated injections, making medication purchasing and inventory management particularly important for retina practices.
That operational reality is important because the alleged kickback in this case was not a vacation, cash payment, fancy dinner, or mysterious briefcase. It involved software.
The PODIS Inventory Management System
According to the Justice Department, ASD acquired an inventory management platform known as PODIS in May 2017. PODIS was designed for retina practices managing inventories and reimbursements involving expensive injectable medications.
Through November 2023, ASD allegedly provided the system free to certain customers that satisfied purchasing requirements. According to the government’s account, customers entering prime vendor arrangements were required to purchase an agreed percentage of specialty medications from ASD. Practices that did not enter those arrangements could be required to pay a monthly fee for PODIS access.
The government also said ASD discontinued PODIS access for certain retina practices that were not ASD customers, including practices that had previously used the platform and were reportedly willing to pay to continue using it.
In ordinary business, giving customers useful software sounds like a perfectly normal sales technique. Sign a contract, get a complimentary dashboard. Buy enough toner, get a printer. Order 47 office chairs, receive enough promotional coffee mugs to open a small museum.
Federal health care law, however, treats incentives differently when they are tied to business involving Medicare and other government health programs.
Why Can Free Software Become a Kickback?
The federal Anti-Kickback Statute generally prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals or the generation of business involving goods or services payable by federal health care programs.
The important word is remuneration. It does not mean cash alone. HHS Office of Inspector General guidance explains that remuneration can include essentially anything of value, including free services and other non-cash benefits.
That distinction matters enormously in pharmaceutical compliance.
A useful software platform has economic value. If one customer normally has to pay for it while another customer receives it free because that customer promises to purchase drugs from the company providing the platform, regulators may examine whether the free technology was intended to influence purchasing decisions.
In the Besse matter, the government alleged exactly that: free access to the inventory management platform served as an incentive for retina practices to purchase specialty drugs from the distributor.
Free Does Not Mean Worthless
This case illustrates one of the easiest compliance mistakes to make. Companies sometimes focus on whether money changed hands rather than whether value changed hands.
Federal regulators have long warned that complimentary services supplied to potential referral sources can constitute remuneration depending on the circumstances. Something does not need a dollar sign attached to it at the moment of transfer to have economic value.
Software subscriptions, administrative support, consulting services, equipment, rebates, free personnel, waived fees, marketing assistance, and valuable data services can therefore deserve the same compliance attention as traditional payments.
How the False Claims Act Enters the Picture
The Anti-Kickback Statute and False Claims Act frequently appear together in health care enforcement cases.
The False Claims Act is one of the federal government’s most important tools for combating fraud involving government money. It can impose liability when a person knowingly submits, or causes another party to submit, false claims for government payment. Potential remedies can include substantial civil penalties and up to three times the government’s damages.
In the Besse settlement, federal authorities alleged that the purchasing incentives resulted in claims being submitted to Medicare, TRICARE, and Department of Veterans Affairs programs.
This creates the legal bridge between an allegedly improper business incentive and federal reimbursement. The government was not simply interested in who received a free software login. Its concern was whether that benefit influenced purchases associated with claims ultimately paid using government health care dollars.
Why Retina Drugs Attract Significant Compliance Attention
Physician-administered specialty medicines occupy an unusual corner of American health care. A practice may purchase expensive medication, maintain the product in inventory, administer it to a patient, and then seek reimbursement from Medicare or another insurer.
For many separately payable Medicare Part B drugs, CMS bases reimbursement on Average Sales Price, commonly called ASP, plus a statutory add-on. CMS says most separately payable Part B drugs and biologics have historically been reimbursed using an ASP-based methodology, generally ASP plus 6 percent, subject to applicable law and adjustments.
Government Accountability Office research has likewise noted the importance of ASP in Medicare’s payment system for physician-administered Part B medicines.
When treatments are expensive and repeatedly administered, distribution contracts, rebates, purchasing incentives, credit arrangements, inventory systems, and price reporting can become financially significant very quickly. A benefit that looks small compared with the national pharmaceutical market can still influence substantial volumes of federally reimbursed purchases.
Who Were the Two Pharmaceutical Whistleblowers?
The whistleblowers were Julianne Nunnelly and Matthew Shanks, both former employees of Regeneron Pharmaceuticals, the manufacturer of Eylea, an aflibercept product used to treat wet AMD and other retinal conditions.
Their lawsuit named Regeneron and other parties. The Besse settlement resolved only part of the broader litigation.
Under the False Claims Act, private individuals known as relators may bring qui tam lawsuits on behalf of the United States when they possess information concerning alleged fraud against government programs.
If the case produces a recovery, whistleblowers can receive a percentage of the proceeds. The Justice Department says successful relators typically receive between 15% and 30% depending on circumstances including government participation in the case.
Nunnelly and Shanks were allocated precisely $250,705.20 from the $1.67 million Besse settlement.
That puts the reward near the lower end of the typical statutory range, but $250,705.20 is still a reasonably persuasive answer to the question, “Was speaking up worth anything?”
Why Pharmaceutical Whistleblowers Matter
Government investigators have subpoena power, sophisticated data analytics, auditors, lawyers, agents, and plenty of acronyms. What they do not automatically have is a desk inside every pharmaceutical company, distributor, medical practice, and billing department.
Employees do.
An insider may recognize that a contract provision described internally as a “customer benefit” is actually linked to purchasing volume. A salesperson might see different pricing rules being applied depending on referrals. A finance employee might notice that certain credits or discounts are excluded from reports. A compliance employee may repeatedly raise a concern only to watch it disappear into what might politely be called the corporate filing cabinet of doom.
This is why the False Claims Act’s whistleblower mechanism is so important. In fiscal year 2024 alone, Justice Department False Claims Act settlements and judgments exceeded $2.9 billion, with qui tam cases accounting for a substantial portion of recoveries. The following fiscal year produced even larger recoveries and another record level of whistleblower filings.
Whistleblowers can provide something investigators cannot manufacture: context. A spreadsheet may show that a customer received a free service. An insider may be able to explain why the service was offered, what management said about it, which sales targets were connected to it, and how the arrangement was presented internally.
What Companies Can Learn From the $1.67 Million Settlement
1. Review Non-Cash Customer Benefits
Compliance reviews should not stop with checks, commissions, rebates, and expense reports. Software, technical support, equipment, staffing, consulting, data analytics, training programs, financing benefits, and administrative assistance can all carry measurable value.
The correct question is not merely, “Did we pay the customer?” It is, “Did we give the customer something valuable, and was that value connected to federal health care business?”
2. Examine Conditions Attached to Free Services
A complimentary tool becomes much more interesting to regulators when obtaining it depends on purchasing a minimum volume or percentage of products.
Contracts should therefore be reviewed not only for stated prices but also for eligibility rules. If access to a benefit disappears when a customer stops purchasing enough reimbursable products, the arrangement deserves careful compliance analysis.
3. Document Legitimate Business Purposes
Health care companies routinely provide valuable services for legitimate reasons. Not every free benefit is automatically illegal. The Anti-Kickback Statute is an intent-based law, and various statutory exceptions and regulatory safe harbors can apply to properly structured arrangements.
The problem arrives when business strategy, communications, contracts, and financial incentives suggest that the benefit was designed to influence federally reimbursed purchasing.
4. Compliance Teams Need Authority, Not Decorative Titles
A compliance department that cannot challenge sales arrangements is roughly as useful as a smoke detector with the batteries stored in another building.
High-risk arrangements should receive independent review before implementation. Compliance personnel should be able to ask who receives the benefit, what it is worth, why it is provided, whether competitors or noncustomers can purchase it, and whether access depends on prescription, referral, or purchasing behavior.
The Case Did Not End With the Besse Settlement
The December 2024 settlement did not dispose of every allegation contained in the whistleblower litigation. The Justice Department had separately intervened against Regeneron concerning different allegations involving Eylea pricing and reimbursement.
In April 2025, a federal judge denied Regeneron’s motion to dismiss the government’s False Claims Act claims concerning allegations that certain credit-card processing fee reimbursements should have affected the Average Sales Price reported for Eylea. That dispute is legally distinct from the Besse inventory-management settlement and should not be treated as a finding against Regeneron.
Court proceedings continued into 2026, including a March 2026 ruling addressing procedural and state-law issues. In other words, the $250,705.20 whistleblower share arose from one settlement within a broader and considerably more complicated piece of litigation.
Practical Experiences and Lessons From Pharmaceutical Whistleblower Cases
The most useful lessons from pharmaceutical fraud investigations often come from understanding what the experience looks like before anybody announces a multimillion-dollar settlement. Real whistleblower cases rarely begin with an employee dramatically declaring, “I have uncovered federal fraud!” while lightning flashes through the conference-room window.
More often, they begin with something painfully ordinary.
An employee sees a sales presentation describing a complimentary service. Someone asks whether the service can be offered to every customer and is told that it is reserved for customers meeting a particular purchasing target. Another employee notices contracts in which the value of a benefit rises with the amount of business directed toward the company.
Initially, none of those facts necessarily proves fraud. What matters is the pattern and the surrounding intent.
Experience Lesson One: Small Details Can Become Major Evidence
Employees closest to a transaction often understand details that appear harmless to outsiders. A contract might describe software as “complimentary.” Internally, however, sales teams may describe it as a reason customers should move their pharmaceutical purchases from a competitor.
That difference in context can matter.
For employees who encounter suspected misconduct, responsible documentation is usually more valuable than dramatic confrontation. Dates, contract terms, participants in meetings, written policies, and ordinary business records can help investigators understand what occurred. Employees should also be careful not to unlawfully access records they are not entitled to possess or disclose legally protected information improperly.
Experience Lesson Two: Internal Reporting Can Reveal the Company’s Response
Many whistleblowers raise concerns internally before approaching regulators or lawyers. Sometimes management investigates and fixes the problem. That is exactly what a healthy compliance system is supposed to accomplish.
Other times, concerns are dismissed without meaningful review. The response itself may become important because investigators frequently examine what decision-makers knew and when they knew it.
A company therefore benefits from documenting how complaints are investigated. Simply marking an email “resolved” does not magically resolve anything. If only compliance worked like an email inbox, civilization would have achieved regulatory perfection around 2004.
Experience Lesson Three: Sales Incentives Deserve Special Attention
Employees working in sales, contracting, finance, market access, reimbursement, or customer support can sometimes see how incentives interact across departments when senior executives cannot.
For example, marketing may describe software as a customer-support service, while finance measures the program according to additional pharmaceutical revenue generated from participants. Compliance needs visibility into both sides of that equation.
A legitimate program should survive the question: “Would we still provide this benefit if the customer purchased fewer federally reimbursed products from us?”
If the answer produces an awkward silence long enough to hear the office refrigerator humming three rooms away, additional review may be appropriate.
Experience Lesson Four: Whistleblower Rewards Are Not Automatic
The $250,705.20 award in the Besse matter should not create the impression that reporting any compliance concern produces a government check.
Qui tam litigation can take years. The government may decline intervention. Allegations may not be substantiated. Cases can be dismissed. Recoveries depend on evidence, legal requirements, causation, procedural rules, and many other factors.
The reward system exists because insiders can assume meaningful professional and personal risk by reporting sophisticated fraud, not because the government operates a loyalty-points program for office disagreements.
Experience Lesson Five: Prevention Is Cheaper Than Investigation
For pharmaceutical manufacturers, distributors, physician practices, and health care technology providers, one of the strongest lessons is that compliance should occur while an arrangement is being designed rather than after investigators arrive.
Before offering valuable technology or services, companies can evaluate fair-market value, eligibility requirements, purchasing conditions, federal program involvement, safe-harbor considerations, written agreements, and the stated business rationale.
A thoughtful review may require lawyers and compliance professionals to ask inconvenient questions. Those questions are inexpensive compared with years of litigation, government investigations, legal fees, damaged business relationships, and headlines featuring words such as “kickback,” “fraud,” and “settlement.”
Conclusion
The pharmaceutical fraud whistleblower case involving ASD Specialty Healthcare and Besse Medical demonstrates why federal health care enforcement extends far beyond obvious cash kickbacks. According to the government, access to valuable inventory management software became problematic because it was allegedly connected to purchasing requirements involving specialty pharmaceuticals reimbursed through federal health care programs.
The resulting settlement totaled $1.67 million, while whistleblowers Julianne Nunnelly and Matthew Shanks were allocated $250,705.20 for their role as relators in the False Claims Act case.
For whistleblowers, the matter shows how insider knowledge can help reveal arrangements that investigators may otherwise struggle to understand. For pharmaceutical businesses, it offers an equally important lesson: when something valuable is given to a health care customer, calling it “free” does not make the compliance questions disappear.
The best defense is usually much less exciting than a courtroom battle: review incentives early, document legitimate purposes, empower compliance personnel, investigate employee concerns seriously, and remember that federal regulators are interested in the economic substance of an arrangement, not merely the label attached to it.
Note: This article summarizes publicly reported federal allegations, settlement information, agency guidance, and court proceedings. The Besse settlement resolved allegations without a judicial determination of liability; although ASD accepted responsibility for specified underlying facts in its settlement, the government’s broader claims should not be interpreted as adjudicated findings.
